Literature DB >> 25372799

Endothelial dysfunction is present only in the microvasculature and microcirculation of early diffuse systemic sclerosis patients.

R T Domsic1, C Dezfulian, Al Shoushtari, D Ivanco, E Kenny, C K Kwoh, T A Medsger, H C Champion.   

Abstract

OBJECTIVES: To evaluate endothelial function and vascular stiffness in large, medium, small and microcirculatory blood vessels in very early diffuse systemic sclerosis (SSc).
METHODS: We studied consecutive early diffuse SSc patients, defined as <2 years from first SSc symptom who did not have a prior cardiovascular event. Age, gender and race-matched controls were recruited. All underwent assessment of aortic pulse wave velocity (PWV), carotid intima-media thickness (IMT) brachial flow-mediated dilation (FMD), digital peripheral artery tonometer (EndoPAT) assessment and laser speckle contrast imaging (LSCI).
RESULTS: Fifteen early diffuse SSc and controls were evaluated. The average age was 49 years, 63% were female and 93% were Caucasian. There were no differences in body mass index, hypertension, diabetes or hyperlipidaemia between controls and SSc patients. Mean SSc disease duration was 1.3 years. In the large central vessels, there was no difference in aortic PWV (p=0.71) or carotid IMT (p=0.92) between SSc patients and controls. Similarly, there was no difference in endothelial dysfunction with brachial artery FMD after ischaemia (p=0.55) and nitroglycerin administration (p=0.74). There were significantly lower values for digital EndoPAT measures (p=0.0001) in SSc patients. LSCI revealed a distinct pattern of microcirculatory abnormalities in response to ischaemia in SSc patients compared to controls. Imaging demonstrated a blunted microcirculatory hyperaemia of the hand with greater subsequent response to nitroglycerin.
CONCLUSIONS: These findings suggest that the earliest endothelial changes occur in smaller arterioles and microvascular beds, but not in medium or macrovascular beds, in early diffuse SSc.

Entities:  

Mesh:

Year:  2014        PMID: 25372799      PMCID: PMC4317362     

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  25 in total

1.  Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study)

Authors:  T J Anderson; E Elstein; H Haber; F Charbonneau
Journal:  J Am Coll Cardiol       Date:  2000-01       Impact factor: 24.094

2.  Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study.

Authors:  Sachin Jadhav; William Ferrell; Ian A Greer; John R Petrie; Stuart M Cobbe; Naveed Sattar
Journal:  J Am Coll Cardiol       Date:  2006-08-17       Impact factor: 24.094

3.  The impact of systemic sclerosis on arterial wall stiffness parameters and endothelial function.

Authors:  Alma Cypiene; Aleksandras Laucevicius; Algirdas Venalis; Jolanta Dadoniene; Ligita Ryliskyte; Zaneta Petrulioniene; Milda Kovaite; Jonas Gintautas
Journal:  Clin Rheumatol       Date:  2008-07-25       Impact factor: 2.980

4.  Increased arterial stiffness as the marker of vascular involvement in systemic sclerosis.

Authors:  Orsolya Timár; Pál Soltész; Szilvia Szamosi; Henrietta Dér; Sándor Szántó; Zoltán Szekanecz; Gabriella Szücs
Journal:  J Rheumatol       Date:  2008-05-15       Impact factor: 4.666

5.  Endothelial dysfunction precedes atherosclerosis in systemic sclerosis--relevance for prevention of vascular complications.

Authors:  G Szucs; O Tímár; Z Szekanecz; H Dér; G Kerekes; S Szamosi; Y Shoenfeld; G Szegedi; P Soltész
Journal:  Rheumatology (Oxford)       Date:  2007-01-23       Impact factor: 7.580

6.  Endothelial function and hemodynamics in systemic sclerosis.

Authors:  Pascal Rossi; Brigitte Granel; Dominique Marziale; Fanny Le Mée; Yves Francès
Journal:  Clin Physiol Funct Imaging       Date:  2010-08-15       Impact factor: 2.273

7.  Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis.

Authors:  J Lekakis; C Papamichael; M Mavrikakis; A Voutsas; S Stamatelopoulos
Journal:  Am J Cardiol       Date:  1998-12-15       Impact factor: 2.778

8.  Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.

Authors:  Myron E Mavrikakis; John P Lekakis; Christos M Papamichael; Kimon S Stamatelopoulos; Ch C Kostopoulos; Stamatios F Stamatelopoulos
Journal:  Int J Vitam Nutr Res       Date:  2003-02       Impact factor: 1.784

9.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Peripheral arterial stiffness and endothelial dysfunction in idiopathic and scleroderma associated pulmonary arterial hypertension.

Authors:  Nir Peled; David Shitrit; Benjamin D Fox; Dekel Shlomi; Anat Amital; Daniele Bendayan; Mordechai R Kramer
Journal:  J Rheumatol       Date:  2009-04-15       Impact factor: 4.666

View more
  11 in total

1.  Atherosclerosis in Systemic Sclerosis: a Modern Controversy.

Authors:  Stefania L Magda; Raluca I Mincu; Carmen M Mihai; Mircea Cinteza; Dragos Vinereanu
Journal:  Maedica (Buchar)       Date:  2015-09

Review 2.  A critical view on cardiovascular risk in systemic sclerosis.

Authors:  Antonios Psarras; Stergios Soulaidopoulos; Alexandros Garyfallos; George Kitas; Theodoros Dimitroulas
Journal:  Rheumatol Int       Date:  2016-07-12       Impact factor: 2.631

3.  Non-invasive digital thermal monitoring and flow-mediated dilation in systemic sclerosis.

Authors:  Tracy M Frech; Maureen A Murtaugh
Journal:  Clin Exp Rheumatol       Date:  2019-09-17       Impact factor: 4.473

4.  Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions.

Authors:  Anthony J Deegan; Faezeh Talebi-Liasi; Shaozhen Song; Yuandong Li; Jingjiang Xu; Shaojie Men; Michi M Shinohara; Mary E Flowers; Stephanie J Lee; Ruikang K Wang
Journal:  Lasers Surg Med       Date:  2018-01-22       Impact factor: 4.025

Review 5.  Cardiovascular disease in systemic sclerosis.

Authors:  Francesca Cannarile; Valentina Valentini; Giulia Mirabelli; Alessia Alunno; Riccardo Terenzi; Filippo Luccioli; Roberto Gerli; Elena Bartoloni
Journal:  Ann Transl Med       Date:  2015-01

6.  Age-Related Progression of Microvascular Dysfunction in Cystic Fibrosis: New Detection Ways and Clinical Outcomes.

Authors:  M Kreslová; A Sýkorová; R Bittenglová; J Schwarz; R Pomahačová; P Jehlička; J Kobr; L Trefil; J Sýkora
Journal:  Physiol Res       Date:  2021-10-30       Impact factor: 1.881

7.  Endothelial dysfunction in patients with systemic sclerosis.

Authors:  Renata Pacholczak-Madej; Piotr Kuszmiersz; Stanisława Bazan-Socha; Joanna Kosałka-Wêgiel; Teresa Iwaniec; Lech Zarêba; Stan Kielczewski; Anna Rams; Jerzy A Walocha; Jacek Musiał; Jerzy Dropiñski
Journal:  Postepy Dermatol Alergol       Date:  2020-09-02       Impact factor: 1.837

Review 8.  Assessing Microvascular Function in Humans from a Chronic Disease Perspective.

Authors:  Alfons J H M Houben; Remy J H Martens; Coen D A Stehouwer
Journal:  J Am Soc Nephrol       Date:  2017-09-13       Impact factor: 10.121

9.  Pilot study to determine whether transient receptor potential melastatin type 8 (TRPM8) antibodies are detected in scleroderma.

Authors:  Ami A Shah; Janelle Montagne; Sun-Young Oh; Fredrick M Wigley; Livia Casciola-Rosen
Journal:  Clin Exp Rheumatol       Date:  2015-08-05       Impact factor: 4.473

10.  Biochemical signaling by remote ischemic conditioning of the arm versus thigh: Is one raise of the cuff enough?

Authors:  Cameron Dezfulian; Maia Taft; Catherine Corey; Gabrielle Hill; Nicholas Krehel; Jon C Rittenberger; Frank X Guyette; Sruti Shiva
Journal:  Redox Biol       Date:  2017-03-18       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.